Assessment of Tobacco Pharmacology and Behavior in Nonclinical Models

The Master IDIQ contract IDIQ-FDA-ATPBNM-23 focuses on scientific research related to tobacco pharmacology and behavioral studies using nonclinical research models. This contract vehicle, originally solicited by the Food and Drug Administration (FDA) in 2017, enables multiple prime contractors to conduct specialized research assessments investigating tobacco-related pharmacological interactions and behavioral patterns in experimental settings. The contract has a shared ceiling value of $10,000,000 and was initially awarded on September 12, 2018, with an ordering period extending through September 12, 2023.

While specific task order details are not provided in the source materials, typical task orders under this vehicle would likely involve laboratory research designing experiments to understand tobacco product interactions with biological systems, behavioral response mechanisms, and potential health implications. Research would presumably be conducted in academic, government, or private research laboratory settings, potentially located near major research institutions or FDA facilities. Prime contractors would likely include specialized research organizations, academic medical centers, and scientific consulting firms with expertise in pharmacological research methodologies. The contract's open set-aside designation suggests opportunities for various sized research organizations to compete for task order awards, with individual task order values potentially ranging from $50,000 to several hundred thousand dollars depending on research complexity and duration.